Company Profile

Archemix Corporation
Profile last edited on: 3/13/19            CAGE: 1YCN5

Aptamer therapeutics for rare hematological diseases
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

300 Third Street
Cambridge, MA 02142
   (617) 621-7700
Location: Single
Congr. District: 07
County: Middlesex

Public Profile

In mid November 2008, in common with many other firms that year, Archemix had filed - but had been unable to get to - IPO. The firm opted instead to merge with the publicly traded NitroMed. In January 2009, NitroMed entered into a merger agreement to be acquired by affiliates of Deerfield Management, a leading healthcare investment organization. Prior to entering into that merger agreement, NitroMed terminated its previously announced merger agreement with Archemix Corporation paying a $1.5 million fee to Archemix. Despite a wealth of working relationships with major players across the industry, the firm went into liquidation mode including selling its Hemophilia assets to Baxter

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2003 2 NIH $737,770
Project Title: Molecular Profiling Array for Cancer Specific Proteins

Key People / Management

  Kenneth Bate -- President

  Errol DeSouza -- President and CEO

  David Epstein -- VP Biology

  John Harre -- Corporate Patent Counsel

  Jane Sheng -- VP Finance

  Martin Stanton -- EVP Corporate Development

  Charles Wilson -- Chief Technology Officer